The Collective Action Roadmap for GI Cancers
The Collective Action Roadmap for GI Cancers is a framework that aims to provide practical guidance and best practices for improving GI cancer care.
The Collective Action Roadmap for GI Cancers is a framework that aims to provide practical guidance and best practices for improving GI cancer care.
GI Cancers Alliance, founded in 2015, is a global organization representing the gastrointestinal cancer community. It unites patient advocacy groups and collaborates with stakeholders to address unmet needs such as screening, awareness, and treatment.
Test Your Biomarkers, a program of the GI Cancers Alliance, is a national educational and awareness initiative empowering the stomach (gastric) cancer community about the importance of biomarker testing in treating stomach cancer.
The GI Cancers Alliance is honored to share our latest research at the 2025 ASCO Gastrointestinal Cancers Symposium on January 23 – 25 in San Francisco, California. Our two abstracts were accepted for poster presentations and for publication in the Journal of Clinical Oncology.
Martha Raymond, MA, of the GI Cancers Alliance, discusses research on unmet needs in patients with gastrointestinal (GI) cancers that the Alliance presented at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
HMP Global, the leading omnichannel healthcare company, today announced the GI Cancers Alliance, Inc. as a partner for the 2024 World Congress on Gastrointestinal Cancer, the premier international forum for GI cancer professionals committed to understanding the very latest research, engaging in global exchange, and advancing clinical outcomes.
Meet the “Chef Without a Stomach”, Hans Rueffert Gastric cancer survivor, father, husband, author, speaker, and teacher, Chef Hans was diagnosed with gastric cancer in 2005 just two weeks after taping the finale of the reality show, Next Food Network Star—and quickly traded in his “Celebrity Chef” status for “Cancer Survivor.”
Download these capsule summary slidesets highlighting key studies from the 2023 ASCO Gastrointestinal Cancers Symposium.
Join CURE® and the GI Cancers Alliance for the Educated Patient® Webinar Series in GI Cancers. Hear from an expert panel of healthcare professionals and advocates who will discuss topics for patients, survivors, and caregivers
The FORTITUDE-101 and FORTITUDE-102 trials are currently enrolling adults with previously untreated advanced or metastatic stomach or gastroesophageal junction (GEJ) cancer.